Anti-Human EGFR Recombinant Antibody (Futuximab) (CAT#: TAB-H35)
Recombinant Chimeric (human/mouse) antibody to Human EGFR. Futuximab (INN) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and also binds to HER1.
Specific Inquiry
IF
Figure 1 Antibodies Internalizes and Degrades EGFRvIII.
Quantification of EGFRvIII detected in spots after antibody treatment for the indicated periods.
Keir, S. T., Chandramohan, V., Hemphill, C. D., Grandal, M. M., Melander, M. C., Pedersen, M. W., ... & Bigner, D. D. (2018). Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. Journal of neuro-oncology, 138(3), 489-498.
WB
Figure 2 Antibodies Internalizes and Degrades EGFRvIII.
The cell line NR6M was treated with negative control mAb (Neg Ctrl mAb), futuximab, modotuximab, or Sym004 for 24 or 48 h, followed by harvest of cell lysates and detection of EGFRvIII by Western blot.
Inhib
Figure 3 Effect of Sym004, and Its Components Futuximab and Modotuximab, in Subcutaneous Glioblastoma Xenograft Tumor Models.
EGFRwt (D08-0308MG) patient-derived GBM xenografts passaged in athymic mice were injected s.c. in the right flank of Balb/c nu/nu mice. Sym004, futuximab, and modotuximab were administered at a dose of 50 mg/kg i.p. twice weekly for 5 weeks (10 treatments in total).
Keir, S. T., Chandramohan, V., Hemphill, C. D., Grandal, M. M., Melander, M. C., Pedersen, M. W., ... & Bigner, D. D. (2018). Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.ournal of neuro-oncology, 138(3), 489-498.
Inhib
Figure 4 Sym004 shows potent inhibition in Subcutaneous Glioblastoma Xenograft Tumor Models.
EGFRwt (D08-0308MG) patient-derived GBM xenografts passaged in athymic mice were injected s.c. in the right flank of Balb/c nu/nu mice. Sym004, futuximab, and modotuximab were administered at a dose of 50 mg/kg i.p. twice weekly for 5 weeks (10 treatments in total).
Keir, S. T., Chandramohan, V., Hemphill, C. D., Grandal, M. M., Melander, M. C., Pedersen, M. W., ... & Bigner, D. D. (2018). Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.rnal of neuro-oncology, 138(3), 489-498.
Specifications
- Host Species
- Mouse
- Derivation
- Chimeric (human/mouse)
- Type
- IgG1 - kappa
- Specificity
- EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) [Homo sapiens]
- Species Reactivity
- Human
- Applications
- IF, WB, Inhib
- CAS
- 1310460-85-5
- Generic Name
- futuximab
- Related Disease
- Colorectal cancers
Product Property
- Purity
- Purity >95% by SDS-PAGE.
Applications
- Application Notes
- The Human EGFR antibody has been reported in applications of Immunofluorescence, Western Blot, Inhibition.
Inhib: 50 mg/kg.
Target
- Alternative Names
- futuximab;1310460-85-5;992 DS;Sym004;EGFR;epidermal growth factor receptor;epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) , ERBB;ERBB1;erythroblastic leukemia viral (v erb b) oncogene homolog (avian);prot
- Gene ID
- 1956
- UniProt ID
- P00533
Related Resources
Bladder Cancer
Non-small Cell Lung Cancer
Pancreatic Cancer
Hepatocellular Carcinoma
Cushing Syndrome
JAK-STAT Signaling Pathway
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Futuximab"
Afuco™ Anti-EGFR ADCC Recombinant Antibody (Futuximab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Chimeric (human/mouse) antibody to Human EGFR. Futuximab (INN) is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and also binds to HER1.
See other products for "EGFR"
Select a product category from the dropdown menu below to view related products.
Please select product type
Single-domain Antibody
Recombinant Antibody
Humanized Antibody
Chimeric Antibody
Human Antibody
Mouse Antibody
Fc Glycosylation
High-mannose Glycoform
Deglycosylated Antibody (Non-glycosylated IgGs)
Chicken IgY Antibody
MHC Tetramer for Cancer
Neutralizing Antibody
Rabbit Monoclonal Antibody
Fab Fragment Antibody
ADCC Enhanced Antibody
scFv Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NABG-056 | Recombinant Anti-Mouse Egfr VHH Single Domain Antibody | ELISA, IHC, FC, FuncS | Llama VHH |
| HPAB-1844-FY | Camelid Anti-EGFR Recombinant Single Domain Antibody (HPAB-1844-FY) | ELISA | Camelid VHH |
| HPAB-1845-FY | Camelid Anti-EGFR Recombinant Single Domain Antibody (HPAB-1845-FY) | ELISA | Camelid VHH |
| HPAB-1846-FY | Camelid Anti-EGFR Recombinant Single Domain Antibody (HPAB-1846-FY) | ELISA | Camelid VHH |
| HPAB-0705-YJ-VHH | Camelid Anti-EGFR Recombinant Single Domain Antibody (HPAB-0705-YJ-VHH) | ELISA, In vivo staining | Camelid VHH |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TAB-H35. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: Neut, ELISA, IF, IP, FuncS, FC, WB
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: FuncS, Inhib, IP, ELISA
-YJ-1.jpg)
Application: ELISA
Application: ELISA, IHC, FC, IP, IF, BL
-1.png)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
